These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 34064793)
1. Does Trypsin Oral Spray (Viruprotect Huijghebaert S; Vanham G; Van Winckel M; Allegaert K Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34064793 [TBL] [Abstract][Full Text] [Related]
2. Comment on Huijghebaert et al. Does Trypsin Oral Spray (Viruprotect Davison G Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612951 [TBL] [Abstract][Full Text] [Related]
3. Reply to Davison, G. Comment on "Huijghebaert et al. Does Trypsin Oral Spray (Viruprotect Huijghebaert S; Vanham G; Van Winckel M; Allegaert K Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612954 [TBL] [Abstract][Full Text] [Related]
4. Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme® a medical device mouth spray against the common cold. Gudmundsdottir Á; Scheving R; Lindberg F; Stefansson B J Med Virol; 2021 Mar; 93(3):1792-1795. PubMed ID: 32975843 [TBL] [Abstract][Full Text] [Related]
5. Early intervention with ColdZyme mouth spray after self-diagnosis of common cold: A randomized, double-blind, placebo-controlled study. Lindberg BF; Nelson I; Ranstam J; Riker DK PLoS One; 2023; 18(1):e0279204. PubMed ID: 36652464 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of ColdZyme® Mouth Spray on prevention of upper respiratory tract infections in a boy with primary immunodeficiency: a case report. Clarsund M; Blom U; Gardulf A J Med Case Rep; 2016 Oct; 10(1):302. PubMed ID: 27799071 [TBL] [Abstract][Full Text] [Related]
8. Coldzyme® Mouth Spray reduces duration of upper respiratory tract infection symptoms in endurance athletes under free living conditions. Davison G; Perkins E; Jones AW; Swart GM; Jenkins AR; Robinson H; Dargan K Eur J Sport Sci; 2021 May; 21(5):771-780. PubMed ID: 32419645 [TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
11. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3- Dinda B; Dinda S; Dinda M Phytomed Plus; 2023 Feb; 3(1):100402. PubMed ID: 36597465 [TBL] [Abstract][Full Text] [Related]
13. Trypsin enhances SARS-CoV-2 infection by facilitating viral entry. Kim Y; Jang G; Lee D; Kim N; Seon JW; Kim YH; Lee C Arch Virol; 2022 Feb; 167(2):441-458. PubMed ID: 35079901 [TBL] [Abstract][Full Text] [Related]
14. Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice. Paull JRA; Luscombe CA; Castellarnau A; Heery GP; Bobardt MD; Gallay PA Viruses; 2021 Aug; 13(8):. PubMed ID: 34452519 [TBL] [Abstract][Full Text] [Related]
15. Virucidal activity of nasal sprays against severe acute respiratory syndrome coronavirus-2. Meister TL; Todt D; Brüggemann Y; Steinmann J; Banava S; Brill FHH; Steinmann J; Pfaender S; Steinmann E J Hosp Infect; 2022 Feb; 120():9-13. PubMed ID: 34752803 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of Mouth Rinses and Nasal Spray in the Inactivation of SARS-CoV-2: A Systematic Review and Meta-Analysis of Idrees M; McGowan B; Fawzy A; Abuderman AA; Balasubramaniam R; Kujan O Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231450 [TBL] [Abstract][Full Text] [Related]
17. Nasal Spray of Neutralizing Monoclonal Antibody 35B5 Confers Potential Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Small-Scale Clinical Trial. Lin Y; Yue S; Yang Y; Yang S; Pan Z; Yang X; Gao L; Zhou J; Li Z; Hu L; Tang J; Wu Q; Lei S; Tian Q; Wang Y; Hao Y; Xu L; Huang Q; Zhu B; Chen Y; Chen X; Ye L Clin Infect Dis; 2023 Feb; 76(3):e336-e341. PubMed ID: 35666466 [TBL] [Abstract][Full Text] [Related]
18. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial. Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494 [TBL] [Abstract][Full Text] [Related]
19. Nitric Oxide and its Derivatives Containing Nasal Spray and Inhalation Therapy for the Treatment of COVID-19. Chavda VP; Patel AB; Vora LK; Singla RK; Shah P; Uversky VN; Apostolopoulos V Curr Pharm Des; 2022; 28(46):3658-3670. PubMed ID: 36284382 [TBL] [Abstract][Full Text] [Related]
20. A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxis-ICE-COVID. Jessop ZM; Gibson J; Lim JY; Jovic TH; Combellack E; Dobbs TD; Carter K; Hiles S; Islam S; Healy B; Humphreys I; Eccles R; Hutchings HA; Whitaker IS Trials; 2022 Sep; 23(1):782. PubMed ID: 36109791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]